StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Immunovant's price to book ratio was 10.4× on Nov 11, 2026, against 8.1× a year earlier. Over the last 5 years it ranged from 1.0× to 22.0×, with a median of 6.9×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202610.4×+1.9
2025Dec 31, 20258.5×+0.5
2024Dec 31, 20248.1×−13.9
2023Dec 29, 202322.0×+16.8
2022Dec 30, 20225.2×+3.4
2021Dec 31, 20211.8×−8.5
2020Dec 31, 202010.3×−41.2
2019Jul 31, 201951.5×–

More Immunovant figures

See a number that looks wrong?